Please assess the completion status of the following clinical trial:

Trial Title: OPTimizing Irradiation Through Molecular Assesment of Lymph Node After Primary Systemic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infiltrating carcinoma of the breast.~* Metastatic lymph nodes (N1) at diagnosis, as determined histologically by Fine Needle Aspiration or Core Needle Biopsy.~* Primary systemic therapy (including antiestrogen or chemotherapy, and targeted therapies).~* Tumour surgery: tumorectomy, quadrantectomy or mastectomy.~* OSNA (ND) or - lymph nodes after primary systemic therapy.~* Age ≥ 18 years old.~* Karnofsky Index ≥ 70 %.~* Signed Informed Consent.~Exclusion Criteria:~* Lymphadenectomy.~* Bilateral breast cancer.~* Males.~* Previous thoracic irradiation therapy.~* Contraindications of radiotherapy (pregnancy, severe collagen diseases).~* Other neoplasms.~* Severe associated comorbidities that, according to the investigator criteria, may interfere with the study evaluations.~* Lymp nodes OSNA -(L), +, ++ after primary systemic therapy.~* Sentinel lymph node biopsy previous to the primary systemic therapy.~* Mammary internal chain affected.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BA3S (Type: ACTIVE_COMPARATOR): Radiotherapy (RT) will be administered, in the breast or thoracic wall, axillary levels I, II and III, and supraclavicular node areas, with optimization of the technique Intentional irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast and nodal areas (axillary I, II, III, and supraclavicular) with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.
- BA2 (Type: EXPERIMENTAL): RT will be administered, in the breast or thoracic wall and axillary levels I and II, with optimization of the technique Incidental irradiation of lymph nodes: Patients will receive a total dose of 50 Gy in the whole breast, but not aimed at nodal areas, with optimization of the technique, in daily fractions of 2 Gy and 5 fractions/week during 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).